Episode Details

Back to Episodes
Pharmaceutical Executive Daily: FDA Approves Reytorpyk for Advanced Breast Cancer

Pharmaceutical Executive Daily: FDA Approves Reytorpyk for Advanced Breast Cancer

Published 4 months ago
Description
In today's Pharmaceutical Executive Daily, Steer Bio discusses its regenerative cell therapy platform for cancer-related lymphedema, FDA approves Celcuity's Revtorpyk as the first pan-PI3K and mTORC1/2 inhibitor for advanced breast cancer, and Insilico Medicine enters a strategic alliance with Bora Pharmaceuticals worth up to $2.5 billion.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us